Rival RET inhibitor data highlighted at thyroid meeting

Loxo Oncology Inc. (NASDAQ:LOXO) and Blueprint Medicines Corp. (NASDAQ:BPMC) each reported updated data at the American Thyroid Association meeting in Washington from clinical trials evaluating their respective ret proto-oncogene (RET) inhibitors to treat RET-altered cancers.

Loxo said Phase I data from the Phase

Read the full 428 word article

User Sign In